Statera BioPharma

About Statera BioPharma

Statera Biopharma, Inc. is a biotechnology company focused on developing innovative treatments to restore immune health. The company operates in the biopharmaceutical sector, which involves creating drugs derived from biological sources to treat various diseases. Statera's primary clients include healthcare providers, hospitals, and research institutions that are involved in treating patients with immune-related conditions.

Statera Biopharma's business model revolves around the research, development, and commercialization of immunotherapy drugs. Immunotherapy is a type of treatment that uses the body's immune system to fight diseases, including cancer and viral infections. The company makes money by developing new drugs and therapies, obtaining regulatory approvals, and then selling these treatments to healthcare providers and institutions. Additionally, Statera may enter into partnerships or licensing agreements with larger pharmaceutical companies to further commercialize their products.

One of Statera's key products in development is STAT 205, which aims to treat acute and post-acute COVID-19 infections by modulating the immune system and reducing inflammation. This drug is currently in the clinical trial phase, with plans to evaluate its effectiveness and safety. Another significant product in their pipeline is STAT 401, an injectable drug designed to extend the duration of disease remission in patients with pancreatic cancer. This product is also in the clinical trial phase, with ongoing efforts to gather data and seek regulatory approval.

Statera Biopharma is actively involved in clinical trials and regulatory processes to bring these innovative treatments to market. The company aims to address high unmet medical needs, such as long-haul COVID-19 syndrome and pancreatic cancer, by providing new therapeutic options that improve patient outcomes.